Myriad Genetics Beats Q4 Expectations, Shares Surge Amid Core Franchise Growth

Myriad Genetics delivered a solid Q4 2025 earnings beat, with positive adjusted EPS and strong test volume growth despite modest revenue decline. MYGN's core franchises—Prolaris and hereditary cancer—showed resilience, offsetting reimbursement headwinds in mental health and weakness in prenatal testing. Cost-cutting drove sharply lower operating expenses and narrowed losses, while gross margins remained stable at 70%, signaling operational stabilization.

Seeking Alpha • 11 hours ago

MYGN Stock Up on Q4 Earnings and Revenue Beat, Gross Margin Down

Myriad Genetics jumps 21% after Q4 earnings beat estimates by 350% and revenues top forecasts, even as gross margin slips and mental health sales decline.

Zacks Investment Research • 13 hours ago

Myriad Genetics, Inc. (MYGN) Q4 2025 Earnings Call Transcript

Myriad Genetics, Inc. (MYGN) Q4 2025 Earnings Call Transcript

Seeking Alpha • a day ago

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

Highl ights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind 1 of $8.1 million. Full year 2025 revenue of $824.5 million decreased 2% year-over-year.

GlobeNewsWire • Feb 23, 2026

Here's What Key Metrics Tell Us About Myriad (MYGN) Q4 Earnings

The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Feb 24, 2026

Myriad Genetics (MYGN) Q4 Earnings and Revenues Surpass Estimates

Myriad Genetics (MYGN) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to earnings of $0.03 per share a year ago.

Zacks Investment Research • Feb 24, 2026

FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test

SALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced the publication of the analytical validation of the FirstGene ® Multiple Prenatal Screen in Clinical Chemistry. The study showed that each component of the test had exceptional sensitivity and specificity.

GlobeNewsWire • Feb 19, 2026

Ahead of Myriad (MYGN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Besides Wall Street's top-and-bottom-line estimates for Myriad (MYGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.

Zacks Investment Research • Feb 18, 2026

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

SALT LAKE CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular testing and precision medicine, will hold its fourth quarter and full year 2025 earnings conference call at 4:30 pm ET on Monday, Feb. 23, 2026. The company's quarterly earnings will be released the same day after the market closes.

GlobeNewsWire • Feb 16, 2026

Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 15, 2026